isolated anti-edar agonist monoclonal antibody or isolated monoclonal antibody fragment or antigen-binding portion or fragment thereof, isolated nucleic acid molecule, expression vector, host cell, transgenic non-human animal, hybridoma, pharmaceutical composition, pharmaceutical kit and, method for producing agonist anti-edar monoclonal antibodies or fragments of isolated monoclonal antibody or antigen binding portions or fragments thereof

摘要

isolated anti-edar agonist monoclonal antibody or isolated monoclonal antibody fragment or antigen binding portion or fragment thereof, isolated nucleic acid molecule, expression vector, host cell, transgenic non-human animal, hybridoma, pharmaceutical composition, pharmaceutical kit, and, method for producing agonist anti-edar monoclonal antibodies or isolated monoclonal antibody fragments or antigen-binding portions or fragments thereof the present invention relates to the preparation of substantially purified anti-edar agonist monoclonal antibodies or isolated monoclonal antibody fragments or portions binding to antigen or fragments thereof. the invention further relates to isolated anti-edar agonist monoclonal antibodies or isolated monoclonal antibody fragments or antigen-binding portions or fragments thereof as well as their use in the treatment of x-linked hypohydrotic ectodermal dysplasia and dental agenesis. the invention also relates to a pharmaceutical composition comprising said isolated anti-edar agonist monoclonal antibodies or isolated monoclonal antibody fragments or antigen-binding portions or fragments thereof and a method of treating x-linked hypohydrotic ectodermal dysplasia and dental agenesis. finally, the present invention relates to a pharmaceutical kit comprising said isolated anti-edar agonist monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.